We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
+1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$3.17B
AUM Growth
+$561M
(+22%)
Cap. Flow
+$1.16B
Cap. Flow
% of AUM
36.62%
Top 10 Holdings %
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$37.9M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$24.5M |
| 3 |
Merck
MRK
|
+$12.3M |
| 4 |
Gilead Sciences
GILD
|
+$11.7M |
| 5 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$11.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Healthcare
ACHC
|
+$16.4M |
| 2 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$9.99M |
| 3 |
Tesla
TSLA
|
+$7.93M |
| 4 |
Larimar Therapeutics
LRMR
|
+$4.64M |
| 5 |
Ocular Therapeutix
OCUL
|
+$3.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 89.52% |
| 2 | Healthcare | 9.63% |
| 3 | Energy | 0.42% |
| 4 | Industrials | 0.14% |
| 5 | Consumer Staples | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADVM
51
DELISTED
Adverum Biotechnologies
ADVM
| $7.71M | 0.24% |
14,280
+9,280
| +186% | +$3.58M |
|
|
BLCM
52
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $7.64M | 0.24% |
+33,152
| New | +$7.11M |
|
|
53
CALL
Gilead Sciences
GILD
$178B
| $7.51M | 0.24% |
797
-1,491
| -65% | -$154K |
|
54
CALL
Ionis Pharmaceuticals
IONS
$8.22B
| $7.46M | 0.24% |
1,209
+829
| +218% | +$40.9K |
|
55
PUT
Alkermes
ALKS
$7.56B
| $7.36M | 0.23% |
1,256
+542
| +76% | +$27.6K |
|
|
MDVN
56
CALL
DELISTED
MEDIVATION, INC.
MDVN
| $7.02M | 0.22% |
1,410
-2,166
| -61% | -$113K |
|
57
CALL
Alnylam Pharmaceuticals
ALNY
$32.7B
| $6.85M | 0.22% |
706
-1,649
| -70% | -$153K |
|
58
Agilent Technologies
A
$42.1B
| $6.75M | 0.21% |
+165,008
| New | +$6.66M |
|
|
COV
59
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $6.7M | 0.21% |
65,537
-1,215
| -2% | -$117K |
|
|
DERM
60
DELISTED
Dermira, Inc.
DERM
| $6.38M | 0.2% |
+352,088
| New | +$5.88M |
|
61
CALL
MannKind Corp
MNKD
$1.17B
| $5.98M | 0.19% |
2,294
-4,394
| -66% | -$124K |
|
|
CEMP
62
CALL
DELISTED
Cempra, Inc.
CEMP
| $5.96M | 0.19% |
2,536
+1,398
| +123% | +$20.9K |
|
|
RGLS
63
DELISTED
Regulus Therapeutics
RGLS
| $5.65M | 0.18% |
+2,936
| New | +$5.22M |
|
64
ProQR Therapeutics
PRQR
$255M
| $5.48M | 0.17% |
253,083
-128,166
| -34% | -$1.95M |
|
65
Microbot Medical
MBOT
$97.4M
| $5.44M | 0.17% |
3,577
+598
| +20% | +$1.09M |
|
66
PUT
Rockwell Medical
RMTI
$31.4M
| $5.36M | 0.17% |
47
| – | – |
|
|
CDMO
67
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $5.2M | 0.16% |
+33,971
| New | +$342K |
|
68
PUT
AbbVie
ABBV
$457B
| $5.05M | 0.16% |
+772
| New | +$48.7K |
|
|
THOR
69
CALL
DELISTED
THORATEC CORPORATION
THOR
| $4.92M | 0.16% |
+1,515
| New | +$44.1K |
|
|
CEMP
70
PUT
DELISTED
Cempra, Inc.
CEMP
| $4.89M | 0.15% |
2,082
+1,016
| +95% | +$15.2K |
|
71
CALL
Perrigo
PRGO
$1.88B
| $4.8M | 0.15% |
+287
| New | +$44.9K |
|
|
DYAX
72
CALL
DELISTED
DYAX CORPORATION
DYAX
| $4.77M | 0.15% |
3,394
+2,522
| +289% | +$31.6K |
|
73
Danaher
DHR
$144B
| $4.72M | 0.15% |
+81,910
| New | +$4.44M |
|
74
CALL
American Tower
AMT
$82.3B
| $4.57M | 0.14% |
462
+169
| +58% | +$16.6K |
|
|
75
MannKind Corp
MNKD
$1.17B
| $4.49M | 0.14% |
172,150
+55,166
| +47% | +$1.56M |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q4 2014 Portfolio in Review
As of Q4 2014, Sabby Management held 323 positions worth $3.17B, up 22% from $2.6B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Sabby Management deployed $1.16B of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1M.
By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 92% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.
- Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1M.
- Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
- Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
- Sabby Management fully exited Acadia Healthcare in Q4 2014, selling an estimated $16.4M.
- Sabby Management's ten largest holdings make up 63% of its $3.17B portfolio in Q4 2014.
- Sabby Management opened 68 new positions and closed 84 in Q4 2014.
- Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17B.
Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.